|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Novartis_Foundation
|
|
gptkbp:acquisition
|
gptkb:Ave_Xis
gptkb:Endocyte
gptkb:The_Medicines_Company
gptkb:Seagen
gptkb:Alcon
Ziarco
|
|
gptkbp:capital
|
$200 billion (2021)
|
|
gptkbp:ceo
|
gptkb:Vas_Narasimhan
gptkb:2018
|
|
gptkbp:clinical_trial
|
over 1000 ongoing
|
|
gptkbp:developed_by
|
gptkb:John_Tsai
|
|
gptkbp:employees
|
approximately 110,000
|
|
gptkbp:founded
|
gptkb:1996
|
|
gptkbp:has_transformation
|
gptkb:Joaquin_Duato
|
|
gptkbp:head_coach
|
gptkb:Jorge_Gomez
gptkb:David_Endicott
gptkb:Marie-France_Tschudin
|
|
gptkbp:headcount
|
Richard Francis
|
|
gptkbp:headquarters
|
gptkb:Basel,_Switzerland
|
|
gptkbp:healthcare
|
generic drugs
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Novartis Group
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:parent_company
|
gptkb:Novartis_AG
|
|
gptkbp:partnerships
|
gptkb:GSK
gptkb:physicist
gptkb:Microsoft
gptkb:Amgen
|
|
gptkbp:philanthropy
|
gptkb:Novartis_Foundation
education initiatives
research funding
disaster relief efforts
access to healthcare programs
|
|
gptkbp:products
|
prescription medications
|
|
gptkbp:research
|
gptkb:Jay_Bradner
|
|
gptkbp:research_and_development
|
$9.1 billion (2020)
|
|
gptkbp:research_areas
|
neurology
oncology
immunology
ophthalmology
cardiovascular
|
|
gptkbp:revenue
|
$48.5 billion (2020)
|
|
gptkbp:specializes_in
|
Richard Francis
|
|
gptkbp:stock_exchange
|
gptkb:NYSE
|
|
gptkbp:subsidiary
|
gptkb:Sandoz
|
|
gptkbp:sustainability_initiatives
|
community engagement
diversity and inclusion
ethical business practices
environmental responsibility
access to medicines
|